Generic Name and Formulations:
Amoxapine 25mg, 50mg, 100mg, 150mg; tabs.
Indications for Amoxapine:
Depression in patients with neurotic or reactive depressive disorders as well as endogenous and psychotic depressions. Depression accompanied by anxiety or agitation.
Initially 50mg 2–3 times daily; may increase to 100mg 2–3 times daily by the end of the first week. May increase above 300mg/day if dose has been ineffective for a period of at least 2 weeks. Maintenance: when effective dosage established, may give as single dose at bedtime (max 300mg). Elderly: initially 25mg 2–3 times daily; may increase by the end of the first week to 50mg 2–3 times daily. May increase carefully up to 300mg/day if necessary.
Within 14 days of MAOIs. During acute recovery phase following MI.
Monitor for clinical worsening, suicidality, and unusual changes in behavior, esp. during initial few months of treatment and during dose changes. Screen for bipolar disorder prior to initiating therapy. Urinary retention. Angle-closure glaucoma. Increased intraocular pressure. Cardiovascular disorders (monitor closely). Seizure disorders. Discontinue if rash, fever, tardive dyskinesia or neuroleptic malignant syndrome develop. Write ℞ for smallest practical amount. Pregnancy (Cat.C). Nursing mothers.
During or within 5 weeks of fluoxetine. Hyperpyretic crises, severe convulsions, and death with MAOIs (see Contraindications). Potentiates alcohol, barbiturates, other CNS depressants. Paralytic ileus with anticholinergics. Monitor serum levels with CYP450 2D6 inhibitors (eg, quinidine, cimetidine, phenothiazines, propafenone, flecainide, others: see literature). Caution with concomitant electroshock therapy.
Drowsiness, dry mouth, constipation, blurred vision, CNS effects (eg, anxiety, insomnia, restlessness, nervousness, palpitations, tremors, confusion, excitement, nightmares, ataxia, alterations in EEG patterns), edema, rash, elevated prolactin levels, nausea, dizziness, headache, fatigue, weakness, excessive appetite, increased perspiration.
Formerly known under the brand name Asendin.
Tabs 25mg, 50mg, 100mg—100; 150mg—30
Clinical Pain Advisor Articles
- Abuse-Deterrent Opioid Formulations: Barriers to Broader Use
- Women Frequently Prescribed High Doses of Opioids After Vaginal Delivery
- Notifications by PDMPs May Not Effectively Reduce Opioid Misuse
- Virtual Reality May Effectively Reduce Sensory, Affective, and Cognitive Pain During Labor
- Medical Cannabis Legalization Associated With Reduced Schedule III Opioid Prescriptions
- Neuropathic Pain Medications
- Higher Buprenorphine Dose May Not Increase Severity of Neonatal Abstinence Syndrome
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Ketamine Infusions May Be Effective for Refractory Headache
- Physical, Psychosocial Activity May Be Protective Against Development of Chronic Pain in Older Adults
- Prioritizing Rest in Hospital Settings: Poor Sleep Increases Costs, Complications, and Mortality
- Pain Catastrophizing Decreases in Rheumatoid Arthritis After DMARD Initiation
- Addressing Commercial Incentives in the Medical Device Industry
- Cancer Patients Treated With Step III Opioids Often Have Sleep Disturbances
- Low Literacy Self-Management Program for Chronic Pain May Be Effective